Skip to main content
Clinical Trials/CTRI/2016/09/007241
CTRI/2016/09/007241
Recruiting
Phase 4

Prospective study of outcomes following neoadjuvant chemotherapy (Gemcitabine and Cisplatin) in patients of muscle invasive urinary bladder cancer

KING GEORGE MEDICAL UNIVERSITY0 sites25 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Health Condition 1: null- CARCINOMA BLADDER
Sponsor
KING GEORGE MEDICAL UNIVERSITY
Enrollment
25
Status
Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Observational

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\.Performance Status (Eastern Cooperative Oncology Group \- ECOG) 0 â?? 2
  • 2\.Histologically confirmed muscle\-invasive bladder cancer
  • 3\.Resectable disease at diagnosis (clinical stages T2 \- T4a, N0 \- 1, M0\) transitional cell carcinoma of the bladder
  • 4\.Patients should have adequate bone marrow function (white blood cell count \> 3\.0 x 109/L, platelet count \> 150 x 109/L)
  • 5\.Renal function (serum creatinine \< 2\.0 mg/dL)

Exclusion Criteria

  • 1\.No history of previous chemotherapy or radiotherapy.
  • 2\.Patients with previous history of other cancers

Outcomes

Primary Outcomes

Not specified

Similar Trials